Madrigal Pharmaceuticals, Inc (MDGL)

Etorro trading 970x250
Madrigal Pharmaceuticals, Inc (MDGL) Logo

About Madrigal Pharmaceuticals, Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. Address: Four Tower Bridge, West Conshohocken, PA, United States, 19428

Madrigal Pharmaceuticals, Inc News and around…

Latest news about Madrigal Pharmaceuticals, Inc (MDGL) common stock and company :

Hedge Funds Are Betting On Madrigal Pharmaceuticals, Inc. (MDGL)
27 Oct, 2021 Yahoo! Finance

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Implied VBR Analyst Target Price: $200
20 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Value ETF (VBR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $200.33 per unit.

Top Stock Picks of Billionaire Nicholas J. Pritzker’s Tao Capital
18 Oct, 2021 Yahoo! Finance

In this article, we discussed billionaire Nicholas J. Pritzker’s investment philosophy and his venture capital investments. We also reviewed the top stock picks of billionaire Nicholas J. Pritzker’s Tao Capital. You can skip our detailed discussion on Pritzker’s investment philosophy and top stock picks, and jump directly to the 4 Top Stock Picks of Billionaire […]

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
07 Oct, 2021 FinancialContent

Upgrades For State Street Corporation (NYSE:STT), Wolfe Research upgraded the previous rating of Peer Perform to ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
04 Oct, 2021 Yahoo! Finance

In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASHCONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver Foundation, the leading patient advocacy organization focused on the diagnosis, treatment and support of Americans with non-alcoholi

Noteworthy Friday Option Activity: MDGL, GM, SWKS
24 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Madrigal Pharmaceuticals Inc (MDGL), where a total volume of 540 contracts has been traded thus far today, a contract volume which is representative of approximately 54,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.5% of MDGL's average daily trading volume over the past month, of 106,895 shares..

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Analysts See 60% Upside For The Holdings of XBI
14 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $209.54 per unit.

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
09 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
16 Aug, 2021 FinancialContent

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Analysts Expect SMMV To Hit $42
12 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $42.34 per unit.

Noteworthy Monday Option Activity: MDGL, MSFT, UNIT
09 Aug, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Madrigal Pharmaceuticals Inc (MDGL), where a total of 1,049 contracts have traded so far, representing approximately 104,900 underlying shares. That amounts to about 95.9% of MDGL's average daily trading volume over the past month of 109,345 shares..

8 Best Stocks to Buy According to Billionaire Nicholas J. Pritzker’s Tao Capital
09 Aug, 2021 Yahoo! Finance

In this article, we will be discussing 8 best stocks to buy according to billionaire Nicholas J. Pritzker based on his hedge fund’s Q1 portfolio. To skip our detailed analysis of Nicholas J. Pritzker’s hedge fund returns, investment philosophy, and history, you can click to skip ahead to 4 Best Stocks to Buy According to […]

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
05 Aug, 2021 FinancialContent
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
02 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
27 Jul, 2021 FinancialContent

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group ...

Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks
27 Jul, 2021 Yahoo! Finance

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Were Hedge Funds Right About Madrigal Pharmaceuticals, Inc. (MDGL)?
26 Jul, 2021 Yahoo! Finance

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31st. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

Oversold Conditions For Madrigal Pharmaceuticals
23 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Stocks That Hit 52-Week Lows On Friday
23 Jul, 2021 FinancialContent

Before 10 a.m. ET Friday, 117 stocks made new 52-week lows. Interesting Points: China Life Insurance Co ...

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
21 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Madrigal Pharmaceuticals, Inc (MDGL) is a NASDAQ Common Stock listed in , ,

970x250